Introduction
Locally advanced primary breast cancers (LAPC) constitute a wide spectrum of disease ranging from slow growing tumours to more aggressive tumours i.e. inflammatory cancers. Multimodal approach using chemotherapy, surgery, and radiotherapy plus or minus endocrine agents has been standard treatment in the more aggressive inflammatory tumours and oestrogen receptor negative (ER-) tumours [1, 2] . Oestrogen receptor positive (ER+) tumours are noted to be less sensitive to chemotherapy than ERtumours [3, 4] .
The incidence of hormone receptor positive breast cancer [5, 6] and the ER content are known to increase with age [7] and the benefit of chemotherapy in primary breast cancer is believed to decrease with age [8] . In the elderly, Tamoxifen has been tried as primary endocrine agent, and versus surgery it has comparable survival [9] [10] [11] [12] .
In LAPC, there are only few randomised controlled trials looking into alternative approaches to treatment and very few looked specifically into ER+ patients. In 2001 we published the result of an randomised controlled trial from our institute on LAPC unselected for ER status, comparing primary endocrine therapy versus multimodal treatment (neoadjuvant chemotherapy, Patey mastectomy, radiotherapy and adjuvant hormone therapy) [13] . It showed no difference in time to distant metastasis or overall survival after a median follow-up of 53 months. Subgroup analysis showed ER+ tumours did significantly better in both groups.
We report our experience of primary endocrine therapy in ER+ LAPC.
Patients and methods
Locally advanced breast cancer was defined as those primary tumours more than 5 cm, with inflammatory features or where there was obvious skin/chest wall involvement or fixed axillary nodes at diagnosis. Distant metastases were ruled out following initial staging investigations. Tumours were considered ER+ with a histochemical (H) score of 20 or above on core biopsy [14] .
Treatment protocol
All patients with LAPC in our institute were seen in a dedicated LAPC clinic, run jointly by breast surgeons and oncologists. All patients with ER-tumours and inflammatory tumours irrespective of ER status receive neoadjuvant chemotherapy if medically fit. Inoperable ER+ tumours are offered primary endocrine treatment and the same for ER+ operable tumours unfit for surgery/chemotherapy. Patients who are ER+ and fit are offered the option of primary endocrine treatment, or chemotherapy as a part of multimodal treatment.
Between Jan 1988 and Jan 2007, 195 ER+, noninflammatory LAPC patients were treated with primary endocrine agents in our institute according to the protocol described, or as a result of recruitment into the above mentioned trial. The choice of initial endocrine therapy agent was tamoxifen or goserelin plus tamoxifen for postand pre-menopausal patients respectively. Tamoxifen was replaced by anastrozole as in both groups since 2003.
Clinical response-was assessed according to UICC criteria [15] . Complete response (CR) was defined as no residual detectable tumour, partial response (PR) was defined as reduction of greater than 50% in the product of the maximum perpendicular diameters of the tumour, with CR + PR collectively known as objective response (OR). Stable disease (SD) was defined as a less than 50% reduction or less than 25% increase in the product of these tumour dimensions and progressive disease (PD) was an increase in the tumour dimension product of greater than 25% or evidence of new disease. Patients who achieved a durable OR or SD for a minimum duration of 6 months were deemed to have derived clinical benefit (CB) from the therapy.
Patients were followed-up every 3 months in the clinic until either death or the last clinic visit on or before Jan 2007. They were followed up for a median duration of 61 months .
Statistical analysis was carried out using the Statistical package for social sciences version 15 (SPSS).
Results
The median age was 69 years (36-92). The median clinical size of the tumour was 6 cm (2-9). All were ER+ with a median H-score of 190 (30-300). One hundred and fifty four patients (79%) received primary endocrine therapy alone and 41 patients (21%) eventually received other modalities of treatment in the form of surgery, radiotherapy and/or chemotherapy as shown in Fig. 1 . The median time to alternative modalities of treatment (Surgery, radiotherapy, chemotherapy) or metastasis was 48 months (2-204). Sixty-three patients (32 %) developed metastasis and 17 of these patients were alive at the end of follow-up. Most of the metastasis was to the bones as shown in Table 1 .
One hundred and eighty-five patients (95%) derived CB from primary endocrine therapy and 10 patients progressed early. Objective response at 6 months was achieved in 47 (24%) patients (8CR and 39 PR) and the majority of patients had SD (138).
Five-year overall survival was 76% (Fig. 2) and 5-year breast cancer specific survival was 86% (Fig. 3) . Metastasis free interval was 59 months. Overall and breast cancer specific survival between patients with OR at 6 months and those with SD were assessed. This showed no statistical difference in overall survival (OR-85% Vs SD-73%; P = 0.351) and breast cancer specific survival (OR-92% vs. SD-80%; P = 0.237). Comparisons were also made between patients who had PD at 6 months and rest of the group. Patients with PD had significantly worse overall 5-year survival (41% vs. 79%; P = 0.0002) and breast cancer specific survival (55% vs. 86%; P = 0.00001) compared to rest of the group. Those who had PD at 6 months had a median H-score of 100 compared to 195 in rest of the group.
Discussion
This study further supports that in ER+ LAPC, primary endocrine therapy is an alternative therapeutic option for selected patients. Direct comparisons with other trials and case series is not appropriate considering varied methodology used in different studies. However the report confirms that in this subgroup of patients, primary endocrine therapy has excellent survival outcome compared to other approaches of treatment i.e. multimodal treatment using chemotherapy (60-80% overall 5 year survival) [16] [17] [18] [19] [20] .
Previous studies have shown the correlation of clinical response to treatment and outcome. Patients with OR have been grouped together, as they are more likely to have better survival than others, at least in the chemotherapy setting [21, 22] . With endocrine treatment, the response is usually slow but sustained. In our series, a significant proportion had SD at 6 months and there was no difference in overall survival and breast cancer specific survival between SD group and those with OR. Patients with PD did significantly worse compared to rest of the group. Similar correlation with outcome and response with endocrine treatment has been documented in both the advanced breast cancer setting and with primary breast cancers [23] [24] [25] . It appears that when assessing response to treatment with endocrine agents, it is more appropriate to consider the rates of non-progression or CB (CR + PR + SD) rather than OR (CR + PR). In our series we have reported a clinical benefit of 95% at 6 months. Our results also suggest that those with early progression tend to have lower ER score. The role of endocrine agents in ER+ metastatic disease has been well established [26, 27] . Locally advanced breast cancers are likely to have micro metastasis at the time of presentation and a proportion develops frank metastasis during their lifetime. In our series, 63 patients (32%) developed metastasis, and of these 27% were alive at the end of follow-up. In these patients who develop metastasis, response to primary endocrine treatment often predicts subsequent response in the metastatic setting. This could help in early and prompt decision on subsequent treatment.
We have reported an overall survival of 76% and this is comparable to other approaches to treatment i.e. multimodal treatment. A recent study from our institute on anthracycline based neoadjuvant chemotherapy as part of multimodal treatment in locally advanced breast cancers from 1996 to 2004 showed a survival of 82% after a median follow-up of 54 months [28] . We compared the above series with primary endocrine therapy during the same time period. A significant proportion of the patients in primary endocrine therapy group were elderly (median age 69 years) compared to neoadjuvant group (median age-49 years) and thus died of other causes with no evidence of metastatic disease. On comparison, there was no significant difference between the two groups with regard to 5-year breast cancer specific survival (PET-86% vs. Neoadjuvant chemotherapy-85%; P = 0.985).
In our sequencing approach to treatment, approximately 80% of patients were treated with endocrine treatment alone, avoiding adverse effects of other noted treatments i.e. chemotherapy, surgery, radiotherapy. Since patients are followed-up at regular intervals, we are able to offer alternative endocrine agents or other treatment for local control as and when they progress.
One fifth of the patients in our series went on to receive other modalities of treatment for local control following progression with endocrine treatment. Apart from our series, very little data is available with regard to local control with primary endocrine treatment in ER+ LAPC. In our previous trial on LAPC patients unselected for ER status comparing initial hormone therapy versus multimodal treatment in 108 locally advanced breast cancers, there was no statistically significant difference in the rates of uncontrolled locoregional disease between groups after a median follow-up of 52 months [13] . In another trial by Williams et al. [29] in 87 LAPC patients unselected for ER status randomised to receive radiotherapy or tamoxifen as first line treatment no difference was seen in the rate of progression of local disease, time of development of metastasis or survival [29] .
In summary, for ER+ non-inflammatory LAPC, primary endocrine therapy has been shown to produce excellent outcome in local control and survival. The superiority of this approach appears to be more marked in patients with strongly ER+ tumours and should be considered as a viable therapeutic option in appropriately selected patients. 
